Reduction (TELMAR) as assessed by magnetic resonance imaging in @entity1 with mild-to-moderate XXXX --a prospective, randomised, double-blind comparison of @entity9887 with @entity1406 over a period of six months rationale and study design.

@entity1 @entity1289 @entity101 @entity918 @entity1406 @entity4346 @entity3591 @entity9887 @entity1002
The @entity9887 Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, @entity9887 , on @entity4346 ( @entity4346 ) compared with the b-blocker, @entity1406 , at similar antihypertensive doses. The rationale is that antihypertensives reduce @entity4346 , a cardiac adaptation to pressure overload, principally by pressure-related effects. Ang II plays a key role in pressure-independent mechanisms causing @entity4346 , and @entity1289 ( @entity1289 ) inhibitors induce more pronounced @entity4346 regression than some other antihypertensives. Blocking Ang II Type 1 receptors may be more effective than @entity1289 inhibition in reducing @entity4346 . TELMAR is a prospective, randomised, double-blind, double-dummy, parallel-group trial. A total of 140 @entity1 (age 18 80 years) with uncontrolled essential @entity101 (mean daytime systolic blood pressure [SBP] >140 mmHg or diastolic blood pressure [DBP] >90 mmHg and/or night-time SBP >120 mmHg or DBP >70 mmHg, measured by ambulatory blood pressure monitoring [ABPM]) and left ventricular mass index related to height (LVMI) >0.8 g/cm for females, >1.1 g/cm for males (defined by magnetic resonance imaging [MRI]) will be randomised to once-daily @entity9887 or @entity1406 . The @entity9887 dose will be 40 mg for the first two weeks, 80 mg for 5.5 months and 40 mg for the last two weeks. @entity1406 will be given at a dose of 47.5 mg for two weeks, 95 mg for 5.5 months and 47.5 mg for two weeks. Concomitant add-on medication with @entity918 and @entity3591 will be allowed. The primary endpoint is the percentage change in LVMI at treatment end versus baseline, using MRI. Secondary variables include blood pressure changes and response rates assessed by ABPM and manual cuff sphygmomanometry, and end-systolic wall stress, systolic @entity1002 ( @entity1002 ) and diastolic @entity1002 determined by MRI. A separate study was performed prior to the main trial to define the normal range of MRI data in an age-matched population.
